Digital therapeutics (DTx) are one of the categories of digital health, which is defined as products that deliver evidence-based therapeutic interventions to patients which are driven by high quality software programs to prevent, manage, or treat conditions. The Covid-19 pandemic accelerated the adoption of DTx globally. This study examines the pricing and reimbursement (P&R) policies for DTx in EU5, US, China and Japan.
Publications